The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
CAR-T cell therapy: current limitations and potential strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To address this, various immunotherapeutic strategies have emerged, including adoptive cell transfer, primarily utilizing genetically modified T cells expressing chimeric antigen receptors (CAR T-cells) to recognize and eliminate cancer cells directly (Sterner and Sterner, 2021). Adjuvant therapies, such as dendritic cell, mRNA, and peptide-based vaccinations, aim to boost the patient’s anticancer”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Research works printed but not linked: 1
- Peter P. Lee (eds.) Tumor Microenvironment (Springer) https://www.springer.com/gp/book/9783030388614
Cited by
Sorted by citations
Items 501–600 of 1,002
Li, X., Chen, T., Li, X., Zhang, H., Li, Y., Zhang, S., Luo, S., & Zheng, T. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00564-w · Cited by 28
Universal CAR cell therapy: Challenges and expanding applications
Wu, Z., Wang, Y., Jin, X. K., & Wang, L. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102147 · Cited by 29
Pfister, F., Carnell, L. R., Löffler, L., Boosz, P., Schaft, N., Dörrie, J., Stein, R. A., Lenz, M., Spiecker, E., Huber, C. M., et al. (2025) · MedComm · doi:10.1002/mco2.70039 · Cited by 28
Hu, T., Lui, K. S., Ko, E. B., Zhao, Y., Zhang, Q., Yang, H., Zheng, M., Chang, H., Guo, B., Cheung, A. K. L., et al. (2025) · Matter · doi:10.1016/j.matt.2025.102038 · Cited by 26
Genetic circuits in synthetic biology: broadening the toolbox of regulatory devices
Müller, M. M., Arndt, K. M., & Hoffmann, S. A. (2025) · Frontiers in Synthetic Biology · doi:10.3389/fsybi.2025.1548572 · Cited by 32
Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy
Balagopal, S., Sasaki, K., Kaur, P., Nikolaidi, M., & Ishihara, J. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00592a · Cited by 27
Bacteriophage T4 as a nanovehicle for delivery of genes and therapeutics into human cells
Rao, V. B., & Zhu, J. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2022.101255 · Cited by 26
Cell Immunotherapy against Melanoma: Clinical Trials Review
Filin, I. Y., Mayasin, Y. P., Kharisova, C. B., Gorodilova, A. V., Kitaeva, K. V., Chulpanova, D. S., Solovyeva, V. V., & Rizvanov, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032413 · Cited by 26
Natural Products for the Immunotherapy of Glioma
Huang, Q., Pan, X., Zhu, W., Zhao, W., Xu, H., & Hu, K. (2023) · Nutrients · doi:10.3390/nu15122795 · Cited by 26
Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future
Kringel, R., Lamszus, K., & Mohme, M. (2023) · Cells · doi:10.3390/cells12131770 · Cited by 26
Kent, A., Crump, L. S., & Dávila, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202950 · Cited by 26
Fusion of Exosomes and Nanotechnology: Cutting-Edge Cancer Theranostics
Agnihotram, R., Dhar, R., Dhar, D., Purushothaman, K., Narasimhan, A. K., & Devi, A. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c01033 · Cited by 27
Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
Zundler, S., Vitali, F., Kharboutli, S., Völkl, S., Polifka, I., Mackensen, A., Atreya, R. N., Neurath, M. F., & Mougiakakos, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1149450 · Cited by 25
Technical pitfalls when collecting, cryopreserving, thawing, and stimulating human T-cells
Browne, D. J., Miller, C., & Doolan, D. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382192 · Cited by 29
Jia, S., Bode, A. M., Chen, X., & Luo, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189166 · Cited by 27
Inorganic Nanoparticle Functionalization Strategies in Immunotherapeutic Applications
Mao, W., & Yoo, H. S. (2024) · Biomaterials Research · doi:10.34133/bmr.0086 · Cited by 30
Challenges in validation of combination treatment strategies for CRC using patient-derived organoids
Benboubker, V., Ramzy, G. M., Jacobs, S., & Nowak-Sliwinska, P. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03173-x · Cited by 29
Giorgioni, L., Ambrosone, A., Cometa, M. F., Salvati, A. L., Nisticò, R., & Magrelli, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910365 · Cited by 27
Advances in CAR-T therapy for central nervous system tumors
Zhou, D., Zhu, X., & Xiao, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00679-6 · Cited by 25
Tan, Y., Qin, S., Zhang, Z., Liu, Y., Zhou, L., Li, B., Nice, E. C., Zhang, Y., & Jing, J. (2025) · MedComm – Oncology · doi:10.1002/mog2.70009 · Cited by 29
Yi, E., Lee, E., Park, H. J., Lee, H. H., Yun, S., & Kim, H. S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03351-5 · Cited by 30
Hurdles to healing: Overcoming cellular barriers for viral and nonviral gene therapy
Honrath, S., Burger, M., & Leroux, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125470 · Cited by 28
Beyond CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy
Zhang, F., Samarkhazan, H. S., Pooraskari, Z., & Bayani, A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104912 · Cited by 26
Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy
Chung, H., Jung, H., & Noh, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212126 · Cited by 28
Stock, S., Kluever, A.-K., Endres, S., & Kobold, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020307 · Cited by 25
Hino, C., Pham, B., Park, D., Yang, C., Nguyen, M. H. K., Kaur, S., Reeves, M. E., Xu, Y., Nishino, K., Pu, L., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10061410 · Cited by 26
Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies
Campisi, M., Shelton, S. E., Chen, M., Kamm, R. D., Barbie, D. A., & Knelson, E. H. (2022) · Cancers · doi:10.3390/cancers14153561 · Cited by 24
Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers
Feng, Q., Sun, B., Xue, T., Li, R., Lin, C., Gao, Y., Sun, L., Zhuo, Y., & Wang, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025608 · Cited by 25
Cellular immunotherapy for medulloblastoma
Schakelaar, M. Y., Monnikhof, M., Crnko, S., Pijnappel, E. W., Meeldijk, J., ten Broeke, T., & Bovenschen, N. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac236 · Cited by 28
RETRACTED: CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment
Akram, F., Haq, I. U., Sahreen, S., Nasir, N., Naseem, W., Imitaz, M., & Aqeel, A. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221132078 · Cited by 25
RetractedBandi, D. S. R., Sarvesh, S., Farran, B., Nagaraju, G. P., & El‐Rayes, B. F. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.06.006 · Cited by 26
Faisal, S. M., Castro, M. G., & Lowenstein, P. R. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.009 · Cited by 26
Li, X., Li, W., Xu, L., & Song, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002818 · Cited by 26
Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
Fang, K., Lee, J., Khatri, I. A., Na, Y., & Li, Z. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007277 · Cited by 25
Sonogenetic control of multiplexed genome regulation and base editing
Liu, P., Foiret, J. L., Situ, Y., Zhang, N., Kare, A. J., Wu, B., Raie, M. N., Ferrara, K. W., & Qi, L. S. (2023) · Nature Communications · doi:10.1038/s41467-023-42249-8 · Cited by 26
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
Manfredi, G. F., Celsa, C., John, C., Jones, C., Acuti, N., Scheiner, B., Fulgenzi, C. A. M., Korolewicz, J., Pinter, M., Gennari, A., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s291553 · Cited by 30
In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials
Nie, S., Qin, Y., Ou, L., Chen, X. S., & Li, L. (2024) · Advanced Materials · doi:10.1002/adma.202310168 · Cited by 25
Boretti, A. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176618 · Cited by 24
Olejarz, W., Sadowski, K. A., Szulczyk, D., & Basak, G. W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147743 · Cited by 26
Zhang, Y., Wang, Y., Mu, P., Zhu, X. G., & Dong, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1470468 · Cited by 24
Zhu, C., Liao, J.-Y., Liu, Y., Chen, Z., Chang, R.-Z., Chen, X., Zhang, B., & Liang, J.-N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02171-z · Cited by 28
The contribution of the monocyte-macrophage lineage to immunotherapy outcomes
Adams, R. C., MacDonald, K. P. A., & Hill, G. R. (2024) · Blood · doi:10.1182/blood.2024025680 · Cited by 26
Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer
Marei, H. E. S., Bedair, K., Hasan, A., Al-Mansoori, L., Caratelli, S., Sconocchia, G., Gaiba, A., & Cenciarelli, C. (2025) · Cancer Cell International · doi:10.1186/s12935-024-03615-8 · Cited by 26
Panahizadeh, R., Panahi, P., Asghariazar, V., Makaremi, S., Noorkhajavi, G., & Safarzadeh, E. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03655-8 · Cited by 26
Engineering resilient CAR T cells for immunosuppressive environment
Khalifeh, M., & Salman, H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.035 · Cited by 25
Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy
Zhang, J., Wang, F., Sun, Z., Ye, J., & Chu, H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03236-x · Cited by 25
Emerging T-cell lymphomas after CAR T-cell therapy
Braun, T., Kuschel, F., Reiche, K., Merz, M., & Herling, M. (2025) · Leukemia · doi:10.1038/s41375-025-02574-x · Cited by 27
Allogeneic CART progress: platforms, current progress and limitations
Shokati, A., Sanjari-Pour, M., Rahnama, M. A., Hoseinzadeh, S., Vaezi, M., & Ahmadvand, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557157 · Cited by 29
Smart CAR-T Nanosymbionts: archetypes and proto-models
Baena, J. C., Victoria, J. S., Toro-Pedroza, A., Aragón, C. C., Ortiz‐Guzman, J., García-Robledo, J. E., Torres, D., Ríos-Serna, L. J., Albornóz, L. L., Rosales, J. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635159 · Cited by 27
Wang, Y., Jiang, C., Zhou, H., & Han, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00705-9 · Cited by 25
In vivo engineering of CAR-T cells: delivery strategies and clinical translation
Gao, Y., Hu, J., An, N., Wen, X., & Li, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00899-y · Cited by 27
Mahasa, K. J., Ouifki, R., Eladdadi, A., & de Pillis, L. G. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022205 · Cited by 24
Khorasani, A. B. S., Yousefi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109041 · Cited by 24
Development and clinical translation of ex vivo gene therapy
Wu, X., He, X., Liu, F., Jiang, X., Wang, P., Zhang, J., & Jiang, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.015 · Cited by 28
Regulation of Transgene Expression by the Natural Sweetener Xylose
Galvan, S., Madderson, O., Xue, S., Teixeira, A. P., & Fussenegger, M. (2022) · Advanced Science · doi:10.1002/advs.202203193 · Cited by 26
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future
Srour, S. A., & Akın, S. (2022) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-7 · Cited by 25
Kim, Y., Li, W., Zhelev, D. V., Mellors, J. W., Dimitrov, D. S., & Baek, D.-S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1124039 · Cited by 24
B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers
Ventin, M., Cattaneo, G., Maggs, L., Jia, J., Arya, S., Ferrone, S., Wang, X., & Ferrone, C. R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193963 · Cited by 24
The Rise of Hypothesis-Driven Artificial Intelligence in Oncology
Xianyu, Z., Correia, C., Ung, C. Y., Zhu, S., Billadeau, D. D., & Li, H. (2024) · Cancers · doi:10.3390/cancers16040822 · Cited by 25
Liang, T., Song, Y., Gu, L., Wang, Y., & Ma, W. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s418837 · Cited by 24
Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I
Sun, X., Watanabe, T., Oda, Y., Shen, W., Ahmad, A. M., Ouda, R., de Figueiredo, P., Kitamura, H., Tanaka, S., & Kobayashi, K. S. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310821121 · Cited by 22
Revesz, I. A., Joyce, P., Ebert, L. M., & Prestidge, C. A. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1492 · Cited by 27
CAR-NK cell therapy in AML: Current treatment, challenges, and advantage
Bahramloo, M., Shahabi, S. A., Kalarestaghi, H., Rafat, A., Mazloumi, Z., Samimifar, A., & Asl, K. D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117024 · Cited by 23
Applications of cell therapy in the treatment of virus-associated cancers
Toner, K., McCann, C. D., & Bollard, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00930-x · Cited by 29
Jing, R., Falchetti, M., Han, T., Najia, M. A. T., Hensch, L. T., Meader, E., da Rocha, E. L., Kononov, M., Wang, S. Y., Bingham, T., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.004 · Cited by 22
Lucia, A. D., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crinò, L., de Souza, P. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515748 · Cited by 25
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors
Zhang, G., Bai, M., Du, H., Yuan, Y., Wang, Y., Fan, W., Zhu, H., Wu, D., He, P., & Xue, B. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s519616 · Cited by 26
Cheng, J., Gao, R., Lyu, Y., Xiong, Z. L., Yang, K., Zhao, X., Huang, X., Xu, L., Guo, L., Wang, W., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c05068 · Cited by 24
Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy
Chen, Y., Liu, Y. A., Nguyen, K. M., Wu, J., Song, S., Lin, K., Rodrigues, P. F., Du, S., Zhou, C., Xiong, K., et al. (2026) · Science · doi:10.1126/science.ads3972 · Cited by 28
Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response
Liu, C., Qi, T., Milner, J. J., Lu, Y., & Cao, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748768 · Cited by 25
Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer
Mohammadi, M., Akhoundi, M., Malih, S., Mohammadi, A., & Sheykhhasan, M. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2325 · Cited by 24
Nanotheranostic Strategies for Cancer Immunotherapy
Nguyen, A., Kumar, S., & Kulkarni, A. A. (2022) · Small Methods · doi:10.1002/smtd.202200718 · Cited by 24
Diverse effects of obesity on antitumor immunity and immunotherapy
Dyck, L., & Lynch, L. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.11.004 · Cited by 24
CAR T-Cell Therapy in Children with Solid Tumors
Kulczycka, M., Derlatka, K., Tasior, J., Lejman, M., & Zawitkowska, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062326 · Cited by 24
Gečys, D., Skredėnienė, R., Gečytė, E., Kazlauskas, A., Balnytė, I., & Jekabsone, A. (2023) · Cells · doi:10.3390/cells12091247 · Cited by 23
Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
Samur, M., Samur, A. A., Corre, J., Lannes, R., Shah, P. S., Anderson, K. C., Avet‐Loiseau, H., & Munshi, N. C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010025 · Cited by 23
Li, Y.-N., Xie, B., Zhang, Y., He, M.-H., Xing, Y., Mu, D., Wang, H., & Guo, R. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i40.5593 · Cited by 23
Recent advancement in targeted therapy and role of emerging technologies to treat cancer
Barot, S., Patel, H. J., Yadav, A., & Ban, I. (2023) · Medical Oncology · doi:10.1007/s12032-023-02184-6 · Cited by 25
Lee, G., Choi, Y., Hong, J., Kim, J., Chae, J., Ahn, S., Ha, H.-J., Jeong, E., Lee, H., & Choi, J. H. (2024) · BioChip Journal · doi:10.1007/s13206-024-00147-1 · Cited by 26
Alves, C. L., Deng, Z., Kermeci, N., & Shih, S. C. C. (2024) · Lab on a Chip · doi:10.1039/d3lc01090b · Cited by 22
Saadan, N. M., Ahmed, W. U., Kadi, A. A., Almutairi, M. S., Al-Wabli, R. I., & Rahman, A. F. M. M. (2024) · ACS Omega · doi:10.1021/acsomega.4c06889 · Cited by 22
Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment
Li, J., Zhang, Y., Fu, T., Xing, G., Cai, H., Li, K., Xu, Y., & Tong, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1487782 · Cited by 22
Focused Ultrasound in Cancer Immunotherapy: A Review of Mechanisms and Applications
Labib, S., Bright, R. K., & Liu, J. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.09.008 · Cited by 25
TIL Therapy in Lung Cancer: Current Progress and Perspectives
Hu, W., Bian, Y., & Ji, H. (2024) · Advanced Science · doi:10.1002/advs.202409356 · Cited by 25
Argueta, S., Wang, Y., Zhao, H., Diwanji, N., Gorgievski, M., Cochran, E. L., Grudzien‐Nogalska, E., D’Alessandro, J. S., McCreedy, B. J., Prod’homme, T., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1501365 · Cited by 26
Li, G., Du, R., Wang, D., Zhang, X., Wang, L., Pu, S., Li, X., Wang, S., Zhang, J., Liu, B., et al. (2025) · Advanced Science · doi:10.1002/advs.202409835 · Cited by 22
Wang, Y., Yang, M. H., Zhang, B.-Y., Zhao, G., Zhou, S., Lu, Z.-D., Xu, C., & Wang, J. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100011 · Cited by 23
Guo, S., & Xi, X. (2025) · Biomarker Research · doi:10.1186/s40364-025-00755-5 · Cited by 22
Lei, S., Li, J., Zhu, M., Zhou, W., Fu, X., Wu, S., Chen, X., Zhang, J., Duan, X., Wang, W., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c18153 · Cited by 23
Recent research progress and clinical status of immunotherapy for colorectal cancer
Huo, Z., Liu, G., & Li, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.089 · Cited by 27
Emerging Risk Factors for Invasive Pulmonary Aspergillosis: A Narrative Review
Elkhapery, A. M. R., Fatima, M., & Soubani, A. O. (2025) · Journal of Fungi · doi:10.3390/jof11080555 · Cited by 24
Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives
Shang, D., Zhou, Z., Shi, R., Wang, Z., Zhang, P., Fu, P., Li, H., Cheng, G., Qin, H., Xie, Z., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02476-7 · Cited by 26
Yagel, G., Rimini, D., von Locquenghien, M., Avellino, R., Barboy, O., Chalan, P., Granot, G., Xie, K., Shlomi-Loubaton, S., Sheban, F., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.11.009 · Cited by 25
Multipurposing CARs: Same engine, different vehicles
Hossian, A. K. M. N., Hackett, C. S., Brentjens, R. J., & Rafiq, S. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.012 · Cited by 24
Kang, D. H., & Kim, I.-H. (2022) · Biomedicines · doi:10.3390/biomedicines10061376 · Cited by 22
Dillman, R. O., Nistor, G. I., & Keirstead, H. S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2198467 · Cited by 25
Cancer Immunotherapy Using Bioengineered Micro/Nano Structured Hydrogels
Askari, E., Barough, M. S., Rahmanian, M., Mojtabavi, N., Sarrami‐Forooshani, R., Seyfoori, A., & Akbari, M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301174 · Cited by 22
CRISPR, CAR-T, and NK: Current applications and future perspectives
Khoshandam, M., Soltaninejad, H., Hamidieh, A. A., & Hosseinkhani, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101121 · Cited by 25
Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer
Wemlinger, S. M., & Cambier, J. C. (2023) · European Journal of Immunology · doi:10.1002/eji.202249947 · Cited by 23
Enhanced cellular therapy: revolutionizing adoptive cellular therapy
Xu, M., Zeng, N., Liu, C., Sun, J., An, Y., Zhang, S.-H., Xu, J., Zhong, X., Ma, S., He, H., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00506-6 · Cited by 24
Metadata
- Authors
- Sterner, R. C., & Sterner, R. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Sterner, Rosalie M.
- Venue
- Blood Cancer Journal
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8024391
- OpenAlex
- W3148729173
- Cited by
- 2,926
- References
- 110
- Citations by year
- 2026: 530 · 2025: 806 · 2024: 726 · 2023: 532 · 2022: 287 · 2021: 42
- FWCI
- 48.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Wisconsin-Madison (T32-GM008692)
- Regenerative Medicine Minnesota (RMM 012819 EPC 003)
- National Institute of General Medical Sciences (T32GM008692)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, solid tumors, hematologic malignancies, CAR-T cell engineering, tumor microenvironment, antigen escape, CAR-T toxicity, tumor infiltration
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Hematologic Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
